DEVELOPMENT AND VALIDATION OF A STABILITY INDICATING UPLC METHOD FOR THE ESTIMATION OF R-TELAPREVIR IN DRUG SUBSTANCE AND PHARMACEUTICAL DOSAGE FORM OF TELAPREVIR BY ENHANCED APPROACH

Authors

  • G. Rajendra Reddy Dr. Reddy’s Laboratories Ltd. Active Pharmaceutical Ingredients
  • P. Siva Jyothi Dr. Reddy’s Laboratories Ltd. Active Pharmaceutical Ingredients
  • P. Ravindra Reddy Dr. Reddy’s Laboratories Ltd. Active Pharmaceutical Ingredients
  • G. Saidi Reddy Dr. Reddy’s Laboratories Ltd. Active Pharmaceutical Ingredients
  • J. K. Indira Priya Dr. Reddy’s Laboratories Ltd. Active Pharmaceutical Ingredients
  • Rubia Lasker Dr. Reddy’s Laboratories Ltd. Active Pharmaceutical Ingredients

Keywords:

UPLC, Stability-indicating method, QbD with Design-of-Experiments approach, ICH guidelines, Forced degradation

Abstract

Objective: To develop a novel, simple, precise and stability indicating reverse phase ultra-performance liquid chromatographic (RP-UPLC) method and validate as per ICH guidelines for the quantification of R-Telaprevir in drug substance and pharmaceutical dosage form of Telaprevir.

Methods: The chromatographic separation was achieved with Acquity UPLC-BEH C-18 column (100 mm X 2.1 mm, 1.7 μm particle size column with mobile phase containing a gradient mixture of Mobile phase-A and B, flow rate of 0.25 ml/min and a detection wavelength of 210 nm. Mobile phase-A contains a mixture of 10 mm di-Potassium hydrogen phosphate anhydrous, pH adjusted to 11.5 with potassium hydroxide and methanol in the ratio 85:15 (v/v) and the mobile phase-B contains a mixture of Acetonitrile, methanol, 2-propanol and ethanol in the ratio 80:10:7:3 (v/v/v/v) respectively. Chromatographic separation was achieved on UPLC in gradient elution mode by QbD with Design-of-Experiments approach.

Results: The method exhibited consistent, high-quality recoveries [100±10%] with a high precision for R-Telaprevir. Linear regression analysis revealed an excellent correlation between peak responses and concentrations (r2value of 0.9996) for R-Telaprevir. The method is sensitive enough to quantifyR-Telaprevir above 0.05% and detect above 0.015% in Telaprevir. Forced degradation studies proved that the method is specific for R-Telaprevir.

Conclusion: An accurate, precise, linear, robust and specific UPLC method was developed and validated for the quantification of R-Telaprevir in drug substance and pharmaceutical dosage form of Telaprevir as per ICH guidelines. The method is stability-indicating and can be used for routine analysis of production samples and to check the stability of samples.

 

Downloads

Download data is not yet available.

References

EMA (European Medicines Agency) CHMP (Committee for Medicinal Products for Human Use) Assessment Report for telaprevir (INCIVO); 2011.

European Association for the study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55(2):245-64.

Aouri M, Moradpour D, Cavassini M, Mercier T, Buclin T, Csajka C, et al. Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir. Antimicrob Agents Chemother 2013;57(7):3147–58.

Marcellin P. Hepatitis B and Hepatitis C. Liver Int 2009;29(1):1-8.

Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-coinfected Persons. N Engl J Med 2004;351(5):451-9.

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus Infection in HIV-Infected Patients. N Engl J Med2004;351(5):438-50.

Schinazi RF, Bassit L, Gavegnano C. HCV drug discovery aimed at viral eradication. J Viral Hepat 2010;17(2):77-90.

Znabet A, Polak MM, Janssen E, De Kanter FJJ, Turner NJ, Orru RVA, et al. A highly efficient synthesis of telaprevir by strategic use of biocatalysis and multicomponent reactions. Chem Commun 2010;46:7918-20.

Barritt AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterol 2012;142(6):1314-23.

McHutchison JG, Everson GT, Gordon SC, JacobsonI M, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New Engl J Med 2009;360(18):1827-38.

Tempestilli M, Mailano E, D’Offizi G, Montalbano M, D’Avolio A, Gasperi T, et al. Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV. IUBMB Life 2013;65(9):800-5.

FDA. Incivek label information. U. S. Food and drug Administration, Washington, DC. 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf.

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Rajender Reddy K, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis c virus infection. New Engl J Med 2011;364:2405-16.

Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. New Engl J Med 2011;364:2417-28.

Australian Public Assessment Report for telaprevir (Australian Government Department of Health and Ageing Therapeutic Goods Administration) AusPAR Incivo Janssen-Cilag Pty Ltd PM-2010-03576-3-2. Available from: http://www.tga.gov.au/pdf/auspar/auspar-telaprevir-121026.pdf

Penchala SD, Tjia J, El Sherif O, Back DJ, Khoo SH, Else LJ. Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer. J Chromatogr B: Analyt Technol Biomed Life Sci 2013;932:100-10.

ICH Validation of Analytical Procedures: Text and Methodology Q2 (R1), in: Proceedings of International Conference on Harmonization; 2005.

ICH Stability Testing of New Drug Substances and Products Q1A (R2), in: Proceedings of International Conference on Harmonization; 2003.

ICH Stability Testing; Photo stability testing of New Drug Substances and Products Q1B, in: Proceedings of International Conference on Harmonization; 1996.

Maltais F, Chun Jung Y, Chen M, Tanoury J, Perni RB, Mani N, et al. In vitro and In vivo isotope effects with hepatitis c protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats. J Med Chem 2009;52(24):7993–8001.

ICH Pharmaceutical Development Q8 (R2), in: Proceedings of International Conference on Harmonization; 2009.

Plackett RL, Burman JP. The design of optimum multifactorial experiments. Biometrika 1946;33(4):305-25.

Manranjan VC, Yadav DS, Jogia HA, Chauhan PL. Design of experiment (DOE) Utilizationto develop a simple and robust reversed-phase HPLC technique for related substances estimation of Omeprazole formulations. Sci Pharm 2013;81:1043-56.

Raju TVR, Kumar SR, Rao IM, Rao NS. Development and validation of a stability indicating HPLC method for the estimation of rabeprazole impurities in pharmaceutical dosage forms by design of experiments. Asian J Pharm Clin Res 2013;6(4):43-51.

Karmarkar S, Garber R, Genchanok Y, George S, Yang X, Hammond R. Quality by design (QbD) based development of a stability indicating HPLC method for drug and impurities. J Chromatogr Sci 2011;49(6):439-46.

Published

01-05-2015

How to Cite

Reddy, G. R., P. S. Jyothi, P. R. Reddy, G. S. Reddy, J. K. I. Priya, and R. Lasker. “DEVELOPMENT AND VALIDATION OF A STABILITY INDICATING UPLC METHOD FOR THE ESTIMATION OF R-TELAPREVIR IN DRUG SUBSTANCE AND PHARMACEUTICAL DOSAGE FORM OF TELAPREVIR BY ENHANCED APPROACH”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 5, May 2015, pp. 200-7, https://mail.innovareacademics.in/journals/index.php/ijpps/article/view/5129.

Issue

Section

Original Article(s)